Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

MaxCyte, Inc. (MXCT)

NMS · Medical Devices

$1.05+0.03 (+2.94%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$112.5M
P/E (TTM)
EPS
$-0.37
Div Yield
52W Range
$0.64–$2.19
Beta
1.66

Company overview

Next earnings: 2026-08-12(15d)

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Peers in Medical Devices

All in industry →

Recent press releases

March 2026

4 months ago8-KHealthcare

MAXCYTE, INC. — 8-K Filing

MXCTMAXCYTE, INC.

# 🧾 What This Document Is This is an **8-K filing**, a mandatory report to the SEC when a major event happens at a public company. This specific filing announces a **key executive change**: the appointment of a new Chief Financial Officer (CFO). It’s a standard, important update for investors and t

Read summaryView on SEC EDGAR

SEC filings

All filings →
1 recent filing shown in the timeline above. View all SEC filings →

MaxCyte, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
3,683,052 sh-55.2%
4,433,693 sh-33.8%
1,292,773 sh+1082.6%
1,028,646 sh● NEW
9,242,587 sh-7.4%
1,488,818 sh+85.4%
966,562 sh-33.4%
663,956 sh+123.1%

People at MaxCyte, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$5.3M
NI -$10.3M
06/25
$2.9M
NI -$12.4M
09/25
$6.8M
NI -$12.4M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.12
Prior: $-0.12
Revenue sparkline